Last reviewed · How we verify
Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy in R0 Gastric Cancer
Although the intergroup 0116 trial was the first to demonstrate that adjuvant chemoradiotherapy offers a significant survival benefit in completely resected gastric cancer,it is more toxic and less effective. It is reasonable to optimize this regimen.
Details
| Lead sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 500 |
| Start date | 2015-12 |
| Completion | 2022-12 |
Conditions
- Gastric Cancer
Interventions
- docetaxel-based chemoradiotherapy
- FU-based chemoradiotherapy
Primary outcomes
- overall survival rate — 3-year (36-month)
survival time was measured from the date of study enrollment to the date of death or last follow-up
Countries
China